Loading company…
Xerient Pharma develops radioprotective treatments for pancreatic and other abdominal cancers.
Founded in 2019 by Guy Yachin and Michael Shtein, Xerient Pharma is based in Houston. It is developing radioprotective therapeutics intended to protect surrounding tissue during radiotherapy for pancreatic and other gastrointestinal cancers. The company plans to repurpose an FDA-approved drug and received venture funding from Peregrine Ventures.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in